Forum topic

1 post / 0 new
Chris Cavanaugh
BIVIGAM Recall announced

MedWatch logoMedWatch - The FDA Safety Information and Adverse Event Reporting Program

BIVIGAM Immune Globulin Intravenous (Human), 10 Percent Liquid, 100 mL Sterile Vial: Recall - Visible Particles Observed

AUDIENCE: Risk Manager, Infectious Disease, Health Professional

ISSUE: During a routine annual reserve inspection, visible particles were observed in lot number 120016 (Expiration Date: March 31, 2014) of BIVIGAM Immune Globulin Intravenous (Human), 10% Liquid. Biotest is voluntarily recalling this lot from the market. Inspections of other lots of product have not shown the presence of visible particles.

BACKGROUND: BIVIGAM is indicated for the treatment of patients with primary humoral immunodeficiency (PI).

RECOMMENDATION: Consignees are asked to examine stocks immediately to determine if you have any of Lot 120016 on hand. If so, discontinue distributing the lot and promptly return all vials to Biotest’s Boca Raton, Florida facility